SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCSeptember 8, 2026

Pleural metastases carried worse two-year survival than contralateral lung metastases in stage M1a NSCLC

Pleural and contralateral pulmonary metastases sit together in the M1a category of the 9th edition of the TNM classification for NSCLC, an arrangement that implies a similar prognosis for both. A retrospective study of 5632 patients from the Netherlands Cancer Registry, published in the European Respiratory Journal, reports that patients with pleural metastases had lower two-year overall survival than patients with contralateral pulmonary metastases, and that the difference was present whether they received chemotherapy, immune checkpoint inhibitor monotherapy or the two combined.
Share

In brief

  • A Netherlands Cancer Registry study of 5632 patients with stage M1a non-small cell lung cancer (NSCLC) treated with systemic therapy between 2010 and 2022 compared pleural metastases with contralateral pulmonary metastases, the two descriptors that the 9th edition of the TNM classification keeps inside the same M1a category.
  • Two-year overall survival was lower with pleural metastases in every treatment group: 18.5% against 26.9% with chemotherapy, 41.6% against 49.5% with immune checkpoint inhibitor monotherapy, and 28.6% against 40.4% with chemo-immunotherapy.
  • The 341 patients with both pleural and contralateral pulmonary metastases had the worst survival, at 12.1% on chemotherapy, 31.1% on immunotherapy and 25.0% on chemo-immunotherapy.
  • Pleural metastases were more common in men, in patients with a worse performance score and in patients given immunotherapy alone, each at p<0.001, so the two groups differed in composition and in the treatment they were given.
  • The authors report the survival difference as independent of the type of systemic treatment and conclude that the M1a category contains prognostic heterogeneity.

Study at a glance

  • Cohort: 5632 patients with stage M1a NSCLC who received systemic treatment between 2010 and 2022
  • Data source: Netherlands Cancer Registry, retrospective real-world data
  • Population: 2701 with contralateral pulmonary metastases, 2590 with pleural metastases, 341 with both
  • Treatment groups: chemotherapy, immune checkpoint inhibitor monotherapy, and chemo-immunotherapy
  • Primary endpoint: two-year overall survival
  • Survival, chemotherapy: 26.9% (95% CI 24.9 to 28.9) with contralateral pulmonary metastases against 18.5% (95% CI 16.6 to 20.4) with pleural metastases
  • Survival, immunotherapy alone: 49.5% (95% CI 43.4 to 55.2) against 41.6% (95% CI 36.6 to 46.5)
  • Both sites involved (n=341): 12.1%, 31.1% and 25.0% across the three treatment groups
  • What was not reported in the abstract: median overall survival, hazard ratios, and whether the survival comparison was adjusted for the baseline differences the authors describe

On chemotherapy, two-year survival was 18.5% with pleural metastases against 26.9% with contralateral lung disease

Among patients treated with chemotherapy, two-year overall survival was 26.9% (95% CI 24.9 to 28.9) for those with contralateral pulmonary metastases and 18.5% (95% CI 16.6 to 20.4) for those with pleural metastases. The confidence intervals do not overlap, and the cohort is large enough that both estimates are tight: 2701 patients in the contralateral group and 2590 in the pleural group.

The absolute difference of 8.4 percentage points is the figure to hold on to, because the same two patients carry the same stage. Under the 9th edition, pleural metastases and a metastasis in the opposite lung are both M1a, and a staging category exists to group patients whose outlook is comparable. These data report that the outlook of the two groups was not comparable.

The difference held across chemotherapy, immunotherapy and chemo-immunotherapy

With immune checkpoint inhibitor monotherapy, two-year survival was 49.5% (95% CI 43.4 to 55.2) with contralateral pulmonary metastases and 41.6% (95% CI 36.6 to 46.5) with pleural metastases. With chemo-immunotherapy the values were 40.4% (95% CI 36.5 to 44.2) and 28.6% (95% CI 24.9 to 32.4). The authors report that the difference in overall survival was present irrespective of the type of systemic treatment.

The consistency across three treatment strategies is what gives the finding its weight. A difference appearing under one regimen alone could be a feature of that regimen. A difference of 7.9 to 11.8 percentage points under all three points instead to the disease site itself, and the widest of the three gaps appeared with chemo-immunotherapy.

Patients with metastases at both sites had two-year survival of 12.1% on chemotherapy

The 341 patients who had both pleural and contralateral pulmonary metastases did worse than either single-site group: 12.1% (95% CI 8.2 to 16.7) with chemotherapy, 31.1% (95% CI 18.4 to 44.7) with immunotherapy alone and 25.0% (95% CI 15.7 to 35.4) with chemo-immunotherapy.

These estimates rest on a much smaller group, and the confidence intervals show it. The immunotherapy estimate of 31.1% spans 18.4 to 44.7, a range of 26.3 percentage points, so the ordering between the two-site group and the pleural-only group under immunotherapy is not established by these numbers. The chemotherapy estimate has the narrowest interval of the three, at 8.5 percentage points wide, and is the firmest of them.

Worse performance score in the pleural group, with no adjusted analysis in the abstract

The two groups differed before treatment started. Pleural metastases were more common in men, in patients with a worse performance score and in patients who received immune checkpoint inhibitor monotherapy, each at p<0.001. Performance score is a recognised prognostic factor in advanced NSCLC, so part of the survival gap may reflect who had pleural disease rather than the pleural disease itself.

The abstract reports these imbalances and reports the survival figures, and it does not state whether the comparison was adjusted for them. No hazard ratios and no median overall survival values appear in it. Registry data of this kind also carries the era effect of a study period running from 2010 to 2022, across which immune checkpoint inhibitors entered first-line treatment, as the study’s own three treatment groups reflect. Whether the full paper reports an analysis adjusted for any of this cannot be told from the abstract.

“Patients with pleural metastases have inferior OS compared to those with contralateral lung metastases. These findings indicate prognostic heterogeneity between M1a descriptors.”Noordhof et al., European Respiratory Journal (2026)

What follows from that conclusion is a staging question rather than a treatment question. The study compared treatments a patient had already been given and was not designed to show that a patient with pleural metastases should receive something different. Its finding concerns the descriptor: two conditions that the 9th edition treats as one category behaved differently over two years, in more than five thousand patients, under every systemic treatment examined.

Sources

  1. European Respiratory Journal. Prognostic implication of malignant pleural metastases in stage M1a non-small cell lung cancer in a real-world Dutch cohort receiving chemotherapy and/or immunotherapy (2026-09-07). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Lizza Hendriks.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
ILCS 2025
Immunotherapies

The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC

} 28 min

A. Filippi
Sep 26 2025
ILCS 2025
Immunotherapies

Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes

} 36 min

P. Forde
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde
Jun 25 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCImmunotherapies

Immunotherapies in NSCLC

} 1h 47 min

P. FordeJ. RemonS. Peters
SCLC by Solange Peters, Giannis Mountzios, Jacob Sands
Jun 17 2025
VIRTUAL ROUNDTABLE
SCLCImmunotherapies

Small Cell Lung Cancer

} 1h 35 min

G. MountziosJ. SandsS. Peters
Girard ADCs
Oct 05 2024
INDUSTRY SYMPOSIUM
Advanced NSCLCADCs

Best Practices in Managing Adverse Events with ADCs in NSCLC

} 18 min

N. Girard
Patient Cases
Oct 04 2024
ILCS 2024
Advanced NSCLCResectable NSCLC

Patient Cases & Open Questions

} 32 min

Sandip Patel & Giannis Mountzios
Oct 04 2024
ILCS 2024
Advanced NSCLC

DEBATE: Balancing Efficacy, Toxicity, and Patient-Centered Care For IO Duration in NSCLC

} 33 min

G. MountziosS. Patel
Jordi Remon
Oct 04 2024
ILCS 2024
Immunotherapies

Tailoring IO in Resectable NSCLC: Personalized Approaches for Improved Outcomes

} 25 min

J. Remon
Nov132026
ILCS 2026

The International Lung Cancer Summit 2026

Learn more about the event

S. PetersA. AddeoM. DasH. HorinouchiT. SequeiraC. LovlyD. PlanchardS. PatelA. CortelliniN. FrostG. MountziosA. Dingemans
Jul 05 2026
ESMO 2026 SYMPOSIUM
SCLC

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.

M. ReckS. PetersG. MountziosN. Reguart
Sep 26 2025
ILCS 2025
SCLC

Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease

} 34 min

R. Manochakian
Sep 26 2025
ILCS 2025
ADCs

The ADC Revolution in Lung Cancer: New Targets, New Opportunities

} 27 min

N. Reguart
Articles
Oct 23 2026
RESEARCH
SCLCImmunotherapies

KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC

J. SandsM. Reck
Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 16 2026
RESEARCH
Advanced NSCLC

Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study

L. Bubendorf
Oct 14 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue

N. Girard
Oct 08 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Amivantamab, lazertinib and bevacizumab gave a 33% response rate after osimertinib in AMAZE-lung

R. StahelM. PérolA. AddeoS. Peters
Oct 06 2026
RESEARCH
Advanced NSCLCImmunotherapies

Two-thirds of patients with PD-L1-high NSCLC received first-line immunotherapy alone in a real-world survey

D. Rodríguez-Abreu
Alfredo Addeo
Oct 05 2026
RESEARCH
Advanced NSCLCTargeted Therapies

A JCO review sets PACC mutations and exon 20 insertions apart from classical EGFR mutations in NSCLC

A. AddeoX. Le
Oct 05 2026
RESEARCH
SCLCImmunotherapies

Second-line therapy in ES-SCLC gave a median OS of 7.1 months in the Austrian LALUCA registry

M. Hochmair
Nikolaj Frost
Oct 04 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

Checkpoint inhibitors were associated with longer survival in NSCLC after allogeneic stem cell transplantation

N. FrostM. ReckA. Cortellini
Oct 04 2026
RESEARCH
SCLCImmunotherapies

Longer OS in Asian than non-Asian patients given atezolizumab plus chemotherapy for extensive-stage SCLC

S. LiuM. ReckC. Rudin
Oct 03 2026
RESEARCH
Advanced NSCLCResectable NSCLCTargeted Therapies

AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy

A. Calles
Oct 03 2026
RESEARCH
Advanced NSCLCTargeted Therapies

KRAS inhibitors in NSCLC: modest survival gains, inevitable resistance and combinations in early trials

V. Noronha
Oct 02 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Sutetinib produced responses in 71% of patients with uncommon EGFR mutations in a phase IIb trial

X. Le
Oct 02 2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies

High tumour mutational burden was associated with more frequent and earlier immune-related adverse events in advanced NSCLC

B. Ricciuti
Oct 01 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Uncommon EGFR exon 19 deletions were associated with shorter PFS on osimertinib in a 111-patient study

H. Horinouchi